Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

New stem cell therapy which mimics how salamanders grow new limbs raises hopes of new regenerative treatments

Human trials could begin as early as next year

John von Radowitz
Monday 04 April 2016 23:15 BST
Comments
The stem cells mimic how salamander regrowth lost limbs
The stem cells mimic how salamander regrowth lost limbs (Getty Images)

A new kind of stem cell raises the prospect of regenerative treatments that mimic the way salamanders grow new limbs, say scientists.

Therapies based on "induced multipotent stem" (iMS) cells could be tested in human trials as early as next year, according to Australian researchers.

The team, from the University of New South Wales, demonstrated a way of producing iMS cells by reprogramming bone and fat cells.

In theory, the cells could be used to repair bone, cartilage, and muscle.

The cells could repair bone, cartilage and muscle (MAURICIO LIMA/AFP/Getty Images)

Unlike other kinds of stem cell that can differentiate into many types of tissue, iMS cells are not thought to run the risk of triggering cancer.

Lead scientist Professor John Pimanda, said: "We are currently assessing whether adult human fat cells reprogrammed into iMS cells can safely repair damaged tissue in mice, with human trials expected to begin in late 2017.

"This technique is ground-breaking."

To date researchers investigating regenerative treatments have experimented with embryonic stem (ES) cells induced pluripotent stem (iPS) cells.

Both behave in a similar way, multiplying indefinitely and having the ability to transform into any kind of body tissue.

While ES cells are natural, obtained from early-stage embryos, iPS cells are made by reprogramming adult cells. But both run the risk of generating cancerous tumours, and iPS cells are created using genes injected by viruses, which is clinically unacceptable.

The iMS cells which are the focus of the new research reported in the journal Proceedings of the National Academy of Sciences have a more limited capacity but claimed to be safer than ES or iPS cells.

The Australian team produced them by inducing "plasticity" in bone and fat cells from mouse and human donors.

The technique involved exposing the cells to a compound called AZA as well as a platelet-derived "growth factor" - a substance that stimulates growth.

It mimics the remarkable way salamanders use plasticity to regenerate lost limbs or tails, said the scientists.

Dr Ralph Mobbs, also from the University of New South Wales, who will lead the human trials, said: "The therapy has enormous potential for treating back and neck pain, spinal disc injury, joint and muscle degeneration and could also speed up recovery following complex surgeries where bones and joints need to integrate with the body."

PA

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in